arXiv · 2610.34513
Post-Progression Treatment Regimes and the Limits of Cross-Trial Survival Transport
Abstract
Models transporting overall survival (OS) effects across clinical trials fail when they ignore the "post-progression treatment regime"---the subsequent therapy rates across biomarker strata and randomized arms. Because this trial-level regime is systematically omitted from published reports, standard correction families are structurally inadequate: crossover adjustments target an unrealistic counterfactual with zero subsequent therapy, erasing critical environmental differences; population adjustments (including MAIC, STC, AIPW, and density ratios) match baseline individual covariates, leaving trial-level regimes mismatched. We show that these correction approaches carry near-identical bias, proving the failure is informational rather than methodological. Simulations demonstrate that ignoring the target setting's landscape can leave the directional sign of the transported effect completely undetermined, even when mechanisms are fully known. Conversely, providing the target regime to a regime-aware estimator successfully recovers the true treatment effect. Code is available at https://github.com/felizzi/post-progression-transport-WMHS-NeurIPS-2026.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Federico Felizzi, Noman Paracha. 2026-10-25. Post-Progression Treatment Regimes and the Limits of Cross-Trial Survival Transport. https://arxiv.org/abs/2610.34513
Cite the original work for its findings. Save a collection to share your selection of sources.